Inside Matters

Can Your Microbiome Rewrite Your Immune System's Food Allergies?

Food allergies can be devastating. For families managing severe reactions, every meal carries risk, and even one mistake can have fatal consequences. But what if we could change the underlying biology rather than just manage avoidance?

Dr James McIlroy explores a fascinating new study showing that faecal microbiota transplantation might help the gut relearn that foods like peanuts aren't a threat. The research points to an elegant mechanism: donor bacteria reshape bile acid metabolism, which then restores regulatory immune cells that suppress allergic responses.

This episode reveals why the small intestine is critical to immune tolerance, how microbial metabolites influence what your immune system does and doesn't attack, and why owning a dog in early life might actually matter for allergy development. We're early in the evidence, but the signal is compelling.

Professor Alexandra Johnstone joins Dr James McIlroy to explore what makes us hungry, what helps us feel full, and why healthier choices are rarely a matter of willpower alone.

A conversation on chrononutrition, protein, food inequality, GLP-1 medicines and the future of public health.

The big idea: Our bodies, habits and surroundings all influence how we eat. Better health therefore needs more than individual resolve: it needs practical advice, supportive environments and policies that make nourishing food easier to choose.

Breakfast, body clocks and the timing of food

Is breakfast really the most important meal of the day? Professor Johnstone’s answer is an emphatic yes—but not because breakfast has any magical property. Her research focuses on chrononutrition: the relationship between what we eat, when we eat it and the body’s roughly 24-hour circadian rhythms.

The timing of the largest meal may not dramatically alter how much energy the body burns, but it can change how eating feels. A larger breakfast appears to help people feel fuller and may make a calorie-reduced diet easier to follow. The body also tends to be more sensitive to insulin earlier in the day.

There is no universal clock-time definition of breakfast. A useful way to think about it is the first meal within two or three hours of waking.

Fasting is a tool, not a loophole

Intermittent fasting and time-restricted eating can be useful for some people, but they are behavioural strategies rather than shortcuts around energy balance. Professor Johnstone favours including the morning meal and offers the practical reminder: eat breakfast like a king and dine like a pauper.

What does a healthy breakfast look like?

From traditional cooked breakfasts to fortified cereals, the conversation explores nutritious options while highlighting the difference between everyday foods and occasional treats.

Hunger and appetite are not the same thing

A clear and helpful distinction between true hunger and appetite, and why reducing eating behaviour to willpower alone is so misleading.

Why protein is filling

Protein is the most satiating nutrient. The episode dives into the science of satiety, the importance of whole-food sources, and why solid protein tends to be more filling than liquid forms.

Fibre does a different—but equally important—job

While protein excels at satiety, fibre is essential for gut health. The trade-offs and benefits of both are explored.

The obesity paradox and fixing the food environment

Obesity is strongly patterned by inequality. The discussion covers food insecurity, the obesogenic environment, retail promotions, and the need for policy changes that make healthier choices easier.

Ultra-processed food: a debate that needs more evidence

A nuanced look at ultra-processed foods, their role in the diet, and what the current science can – and cannot yet – tell us.

GLP-1 medicines: powerful treatment, unanswered questions

The benefits, limitations, and challenges of GLP-1 medications, including muscle preservation, long-term use, and access/inequality concerns.

Alcohol, Mediterranean patterns and the value of connection

The role of social connection, shared meals, and balanced enjoyment of food and drink.

A practical takeaway: build patterns, not perfection

Realistic, compassionate advice for building sustainable eating habits without shame or moral judgment.

What comes next

Professor Johnstone shares her vision for the future of nutrition science, including better guidance for shift workers, updated protein recommendations, and improved food systems.

About the Conversation In this episode of Inside Matters, host Dr James McIlroy speaks with Professor Alexandra Johnstone, Chair of Nutrition at the University of Aberdeen.

Timestamps:

For years, the spotlight in microbiome research has been firmly on the gut. We’ve learned that diversity there is generally a good thing—linked to resilience, health, and better outcomes.

But what if one of the most important microbiomes in the body follows completely different rules?

In a recent conversation, Dr James McIlroy sat down with Professor David MacIntyre, Director of the Robinson Research Institute, to explore a rapidly emerging field: the female reproductive tract microbiome.

What they uncovered challenges many assumptions—and could transform how we think about pregnancy, birth, and early life health.

When we talk about the gut microbiome, diversity is often considered a hallmark of health.

The reproductive tract? It’s the opposite.

In healthy women, this environment is typically:

This might sound counterintuitive—but it’s by design.

Certain Lactobacillus species—particularly Lactobacillus crispatus—play a protective role by:

In short, they create a stable, protective ecosystem.

When this balance is disrupted and diversity increases, it’s often linked to:

One of the most surprising insights?

Humans are the only species known to have a Lactobacillus-dominated reproductive microbiome.

Even our closest primate relatives don’t share this feature.

That suggests this system evolved relatively recently—and likely offers a meaningful biological advantage, particularly in pregnancy and childbirth.

Preterm birth—defined as delivery before 37 weeks—affects around 1 in 10 pregnancies globally and remains a major medical challenge.

The microbiome appears to play a key role, particularly in early preterm births.

But if inflammation starts too early, it can trigger premature labour.

A Lactobacillus-dominant microbiome helps:

When this balance is lost:

Once inflammation starts, it’s very difficult to switch off.

That’s why prevention is so important.

Several factors can shift the microbiome away from its protective state:

Even small changes in pH or environment can allow harmful bacteria to gain a foothold.

One of the most exciting areas of research is using the microbiome as a predictive tool.

Scientists are working towards:

New technologies can now analyse a simple swab and generate a metabolic “barcode” in minutes—potentially enabling rapid screening.

The long-term vision?

If we can measure it, can we fix it?

Despite widespread marketing, there’s little evidence that oral probiotics reliably reach or colonise the reproductive tract.

They may have indirect benefits—but they’re not an efficient delivery method.

More promising is direct delivery of beneficial bacteria.

A recent clinical trial explored a vaginally delivered strain of Lactobacillus crispatus:

A larger, definitive trial is now underway in the UK.

Inspired by faecal transplants, researchers are exploring vaginal microbiome transplants.

Early studies show potential—but challenges remain:

For now, this remains experimental.

The microbiome’s role doesn’t stop at pregnancy.

During vaginal birth, babies are exposed to their mother’s microbes—an important early “seeding” event.

Babies born via caesarean section:

There’s growing interest in “vaginal seeding” for C-section babies—but:

Looking ahead, this field is moving towards a precision medicine approach.

Instead of treating all pregnancies the same, we may soon:

The goal?

Not just preventing complications—but optimising pregnancy from the start.

This isn’t just about microbes—it’s about long-term health.

By improving the maternal microbiome, we may:

As Professor MacIntyre puts it, we’re on the cusp of a major shift—from reacting to problems to preventing them before they begin.

Dr Debra Silberg joins Inside Matters for a deep, wide-ranging conversation on gut health, drug development, and the future of microbiome therapeutics.

Dr Silberg is the Chief Scientific Officer at Beyond Celiac, a former global clinical leader at Shire/Takeda and AstraZeneca, and one of the most respected figures in GI medicine and microbiome science.

In this episode, we explore:

Dr Silberg also shares insights from her work with Finch Therapeutics, her role at Beyond Celiac, and her experience advising the team at Biotics.

If you’re interested in gut science, the microbiome, diet, or how modern medicines are built from the ground up, you’ll get a huge amount from this conversation.

Be well, trust your gut — and thanks for listening.

00:00 Introduction to Dr Debra Silberg

00:54 Dr Silberg's Career Journey

02:26 Insights on Gut Health and Microbiome

04:05 Understanding GI Diseases and Treatments

07:41 The Role of Diet in Gut Health

15:59 Celiac Disease and Gluten Sensitivity

25:04 Exploring the Microbiome

27:43 Exploring Therapeutic Approaches to the Microbiota

31:36 Challenges in Microbiome Drug Development

34:22 The Gut-Brain Connection and Mental Health

39:13 Transitioning from Academia to Pharma

41:45 Insights into Drug Development and Success Stories

44:55 The Long Journey of Drug Development

52:01 The Role of AI in FDA Reviews

55:04 Quick Fire Round: Future of Microbiome Research

You must not rely on the information in this video as an alternative to medical advice from your doctor or other professional healthcare provider. If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider. If you think you may be suffering from any medical condition you should seek immediate medical attention. You should never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of the information in this video.

In this episode, Dr James McIlroy chats with Dr Tanya Mongan, clinical associate professor and gastroenterology consultant at the University of Nottingham. Dr Mongan specialises in gut health, particularly the gut–brain connection and faecal microbiota transplantation (FMT).

She talks us through the current state of FMT, why it works so well, and how it’s becoming an increasingly important treatment for conditions like inflammatory bowel disease. We also explore her cutting-edge research into microRNA-based medicines—a new field examining tiny molecules that can help protect the gut and may one day be used to treat conditions linked to an unhealthy microbiome, including cystic fibrosis and neurodegenerative diseases.

This episode breaks down the complexities of the microbiome in an easy-to-understand way, covering everything from the limits of current testing to the promise of personalised gut treatments. Dr Mongan also shares insights into exciting new tools such as organ-on-chip models, nano-delivery systems for microRNAs, and even zebrafish models used in gut research.

If you want to understand where gut science is heading, what’s real and what’s hype, and how future therapies may become more precise and personalised, this is a must-listen.

Chapter Markers

00:00 Introduction to Dr Tanya Mongan and gut health

Revolutionising Liver Health: The Link Between Gut Health, Genetics, and Lifestyle

In this episode, we dive deep into the intricate connections between liver health, gut health, genetic predispositions, and lifestyle factors. Our guest, Gary, a seasoned physician and entrepreneur, shares his extensive experience from pioneering liver disease research in the 90s to running a successful metabolic clinic focused on functional medicine today. Learn about the evolution of understanding fatty liver diseases like NASH and MASH, the impact of processed foods, and the groundbreaking treatments emerging, including the promising effects of GLP-1 therapies. Gary also discusses the pivotal role of a clean diet, exercise, and quality sleep in managing liver health, and the challenges of implementing these changes in a clinical setting. Don't miss this insightful conversation packed with practical advice and forward-thinking approaches to improving liver and overall metabolic health.

00:00 The State of Food Quality in America vs Scotland

Takeaways

In this episode, Dr. James McIlroy interviews Dr. Ran Blekhman, an associate professor at the University of Chicago, about the microbiome and its role as 'our second genome.'

Dr. Blekhman shares his research findings on the genetic and environmental factors that shape the microbiome, the heritability of microbial genes, and the relationship between the human genome and microbiome. They also discuss Dr. Blekhman's groundbreaking research that analysed over 168,000 samples to understand global microbiome patterns, the influence of early-life microbiome development, and the potential of microbiome-based diagnostics and therapeutics. Tune in for a comprehensive dive into one of the most promising areas of genetic and microbial research.

00:00 Introduction to Dr. R Blackman and the Microbiome

In this episode of Inside Matters, I'm joined by Dr Johan van Hylckama Vlieg, Chief Scientific Officer at Freya Biosciences. As a global leader in microbiome research, Freya is pioneering innovative approaches to women’s health through biotherapeutics that are rooted in groundbreaking microbiome science.

00:00 Introduction to Dr. Johan van Hylckama Vlieg and Freya Biosciences

Dr van Hylckama Vlieg has spent more than 20 years exploring the vast and complex world of the microbiome — the trillions of microbes that live in and on our bodies. These tiny organisms play a huge role in our health. Over time, science has moved from simply identifying these microbes to understanding how they influence our immune system, metabolism and overall wellbeing.

Yet despite this progress, turning those discoveries into real treatments remains a challenge. Dr van Hylckama Vlieg explained that while the science is compelling, the industry needs solid clinical data to bring investors and pharmaceutical companies on board. He sees microbiome-based immunotherapy as a particularly exciting area where transformative breakthroughs could lie ahead.

Freya Biosciences has chosen to focus on the female reproductive tract — a part of the body where the microbiome is less complex than in the gut but just as important. Dr van Hylckama Vlieg spoke about the key role of lactobacilli in maintaining vaginal health. When these helpful bacteria are dominant, they protect against infections and support fertility. When the balance is lost, a state known as dysbiosis, the risks rise significantly.

He also highlighted a wider issue — the historical lack of funding and focus on women’s health. This is something Freya and others in the field are determined to change, and their research is already moving things in the right direction.

One of Freya’s most innovative developments is vaginal microbiota transplantation or VMT. Inspired by the success of faecal microbiota transplants for gut health, this approach involves transferring a healthy vaginal microbiome into someone with dysbiosis. Early results are promising. Many women show a successful shift to a healthier microbial state.

Looking ahead, the goal is to leverage the successes of these natural transfers and develop targeted microbial treatments that can be scaled up. This could lead to safe and widely available therapies that restore balance and improve reproductive health.

Reflecting on his previous experience at Kaleido, another microbiome venture, Dr van Hylckama Vlieg spoke about the need for strong links between science, clinical design and commercial strategy. Though Kaleido faced setbacks, the underlying science remains solid and is being explored by others in the field.

His outlook remains positive. With more trials underway and deeper understanding of how microbiomes influence disease, there is hope that these therapies will move from the lab into everyday medicine. Particularly in areas like immunotherapy, the potential to address root causes rather than just symptoms could be a game-changer.

Dr van Hylckama Vlieg’s insights offer a compelling look into a rapidly evolving area of science. As researchers and companies like Freya push forward, the possibilities for transforming healthcare through the microbiome are growing fast. From improving fertility to preventing infections, these tiny organisms may hold the key to better outcomes for millions — especially in areas of health that have long been underserved.

The Gut-Health Revolution | Dr Chris Damman on Nutrition, Microbiome & the Future of Wellness

Dr Chris Damman brings decades of experience from the biotech world and leading global foundations to share his vision for the future of health and nutrition. In this episode, we dive deep into the transformative power of gut health and the emerging science shaping how we eat and live.

Gut Health: Ancient Wisdom Meets Modern Science

Next-Generation Nutrition: The 4 Fs

GLP-1 Agonists: A Promising Yet Cautious Path

Weed, Seed, and Feed: A Gut Health Strategy

Fermented Foods & Probiotics

The Future: Nutrition Tech & Smarter Choices

Conclusion

Chapters:

Irritable bowel syndrome (IBS) is often brushed off as little more than an inconvenience. But in a recent conversation between Dr James McIlroy and Professor Yan Yiannakou, a consultant gastroenterologist with decades of experience, it’s clear that IBS is far more serious than many realise. Their discussion sheds light on the true impact of IBS and the exciting developments in its treatment.

IBS: A Closer Look

Affecting around 10–15% of the population, IBS can be life-altering for some. Beyond the discomfort, it can seriously disrupt work, relationships, self-confidence, and mental health. Historically, because there was little visible evidence of physical disease, IBS was wrongly considered a psychological condition. Thankfully, this outdated view is changing. New research highlights real physiological changes in the gut, such as immune activation and heightened sensitivity, helping to validate patients’ experiences.

Recognising the Symptoms

Professor Yiannakou explains that IBS typically involves abdominal pain, changes in bowel habits, bloating, and excess wind. Previously labelled a “syndrome” because its causes weren’t well understood, IBS is now recognised as a real disease linked to changes in the gut microbiome and immune system. Symptoms can vary from mild discomfort to severe, debilitating pain that significantly affects daily life.

Breaking Down Misconceptions

A key part of the conversation tackles the myth that IBS is “all in the mind.” While stress can worsen symptoms, it is not the root cause. Dismissing IBS as purely psychological can deepen patients’ distress and delay proper care. Professor Yiannakou stresses the importance of treating IBS as the genuine, physical condition it is.

What Causes IBS?

Although the exact causes are still being explored, IBS often develops after a major gut infection, which can disrupt the gut’s immune system. Treatments are now moving beyond simply managing symptoms like constipation or diarrhoea, with more focus on addressing underlying causes, particularly gut microbiome imbalances.

Hope for the Future

Research into the microbiome’s role in IBS is opening up new treatment options. Early trials of microbiome-based therapies show promising results, but more work is needed to bring these breakthroughs into everyday clinical practice.

Final Thoughts

Professor Yiannakou’s insights highlight the urgent need for better recognition and treatment of IBS. Dispelling outdated myths and focusing on the true physiological causes of the condition offers real hope for those living with IBS. As research continues, the future looks brighter for more effective, lasting treatments.

The conversation touches on everything from genetic influences on obesity and the challenges of sustained weight loss, to the exciting potential of GLP-1 drugs and next-generation probiotics. There’s also a fascinating look at how the microbiome might act as both a diagnostic and therapeutic tool in future medicine.

Finally, Max shares highlights from his book The Power of Hormones, which brings together history, science, and practical advice for anyone curious about how hormones and the microbiome shape our lives.

This episode offers an insightful look at where cutting-edge science meets real-world potential—and why the microbiome could be the key to a healthier future.

Timestamps:

00:00 Introduction to Professor Yan Yau and IBS